NEW YORK (GenomeWeb News) – Life Technologies today said that it has inked a companion diagnostics deal with pharmaceutical firm Merck Serono for an undisclosed oncology target and eventually other therapeutic areas.

Under the non-exclusive agreement, Life Tech will employ a wide range of its technology platforms, including next-generation sequencing, Sanger sequencing, qPCR, and flow cytometry. Life Tech said that it the alliance is successful, the firms would sign another agreement, under which the firm would commercialize the companion diagnostics in agreed-upon territories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.